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Abstract
Molybdenum cofactor deficiency is a fatal neurological disorder, which follows an autosomal-recessive trait and is characterized by
combined deficiency of the enzyme, sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase. Early detection of molybdenum cofactor-
deficient patients is essential for their proper care and genetic counseling of families at risk. We demonstrate the use of S-sulfonated
transthyretin (TTR) as a marker for molybdenum cofactor deficiency. Plasma or sera obtained from 4 patients with molybdenum cofactor
deficiency and 57 controls were studied by electrospray ionization mass spectrometry (ESIMS) following selective enrichment of TTR by
immunoprecipitation using protein G/A agarose. The data obtained from molybdenum cofactor deficiency samples indicated a strong
increase in the peak height of S-sulfonated TTR. A more significant difference was revealed if the peak height ratio of S-sulfonated TTR and
the sum of the other oxidized TTR were determined. By accurate determination of the ratio, the samples of molybdenum cofactor deficiency
patients could clearly be distinguished from controls without molybdenum cofactor deficiency.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
We reported previously a unique isoform of serum trans-
thyretin (TTR), which was S-sulfonated by excessive sulfite
in vivo in a patient with molybdenum cofactor deficiency
(MCD) [1]. Molybdenum cofactor is essential for the func-
tion of the enzymes sulfite oxidase, xanthine dehydrogenase
and aldehyde oxidase [2]. MCD and isolated sulfite oxidase
deficiency result in a severe clinical phenotype, which is, in
most cases, characterized by nontreatable convulsions pre-
senting early after birth. Besides neurological symptoms and
anatomic brain anomalies, ectopic lenses, dysmorphic signs,
hypertonicity and hypotonia are frequent features. Due to the
lack of sulfite oxidase activity, sulfite accumulates and
sulfate production decreases. The presence of elevated levels
of sulfite leads to the accumulation of S-sulfocysteine formed
by a direct reaction of sulfite with cysteine [2]. The for-
mation of protein-sulfonated compounds (RS–SO3
 ) in the
albumin and fibronectin of several animal species exposed to
sulfur dioxide or to sulfite/hydrogen sulfite has been reported
[3]. TTR contains a single free cysteine at position 10. We
predicted the elevation of S-sulfonated TTR in the sera of
sulfite oxidase-deficient patients, and demonstrated it in a
single case of MCD by electrospray ionization mass spec-
trometry (ESIMS) [1]. To reveal the modified structure of
TTR, ESIMS with immunoprecipitated TTR was success-
fully applied [4].
The S-sulfonated TTR signals were also clearly high in
additional MCD samples, in contrast to most control sam-
ples that presented low S-sulfonated TTR peaks. However,
elevated S-sulfonated TTR was also observed in some of the
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control samples, although those patients did not have MCD.
Commercially obtained TTR also showed a rather high peak
of S-sulfonated TTR (f 15%). High peaks of S-sulfonated
TTR were often detected (ca. 20%) in TTR prepared from
rabbit sera. Our original ESIMS method with immunopre-
cipitated TTR has been applied in several institutions to
detect TTR variants in sera from patients with familial
amyloidotic polyneuropathy [5–7]. In some of the samples,
which were studied in this regard and were not from MCD
patients, rather high signals corresponding to S-sulfonated
TTR, which is 80 Da larger than free TTR, were also
reported [6]. To distinguish MCD from these ambiguous
cases, we here describe an improved method for sample
preparation and calculation of results.
2. Materials and methods
2.1. Specimens
Plasma or sera of 4 patients withMCD as diagnosed on the
basis of clinical features, metabolite studies, enzyme assays
in cultured skin fibroblasts and mutation analysis, and 57
samples obtained from children with a variety of diagnoses,
but neither MCD nor isolated sulfite oxidase deficiency, were
analyzed. One case of MCD was already reported previously
[1]. The ages of the MCD patients at the time of sampling
were 3 days, 3 months, 2 and 3 years. The ages of the controls
were distributed from 1 month to 13 years.
2.2. Sample preparation
We previously reported a convenient method for prepar-
ing protein samples for application to soft ionization MS
[8–10]. The test serum was mixed with antiserum against
the target protein, and the generated immunoprecipitates
were subsequently washed with 0.15 M sodium chloride
and water. The mixture was applied directly to on-line high
performance liquid chromatography (HPLC)/ESIMS. Most
samples were successfully analyzed by this method. How-
ever, the preparation method was not good enough to
determine an accurate ratio for the S-sulfonated TTR and
TTR isoforms. The remaining albumin in immunoprecipi-
tates coeluted with S-sulfonated TTR in the HPLC system,
and disturbed the measurement of this fraction. To wash out
serum protein extensively, we used protein G/A agarose to
form large immune complex particles. ProteinGplus/Protein
A Agarose (50 Al of suspension) (Oncogene Research Prod-
ucts, cat# IP05, lot# D14269, Boston, MA) was washed three
timeswith 0.5ml of 0.15M sodium chloride. AntihumanTTR
(prealbumin) antiserum (25 Al) (SIGMA, lot# 19H4822, St.
Louis, MO) was added to the agarose, and the mixture was
Fig. 1. Deconvoluted ESIMS spectra of TTR from a control infant (a), a
patient with MCD (b), and a second infant without MCD (c), but with a
rather high peak of S-sulfonated TTR. A, free TTR; B, TTR conjugated
with cysteine; C, TTR conjugated with cysteinylglycine; D, TTR
conjugated with glutathione; S, S-sulfonated TTR; *, modified TTR in
which a side chain of cysteine residue is cleaved, and changed to glycine.
The assignment of each peak was discussed in a previous paper [10]. y, the
observed molecular mass corresponds to TTR in which cysteine is oxidized.
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shaken for 30 min at room temperature. The resulting agar-
ose–antibody complex was washed with 0.5 ml 0.15 M
sodium chloride four times. Subsequently, a 10 Al sample
serumwas mixed with the washed complex and shaken for 30
min. The generated precipitates were washed with 0.5 ml of
0.15 M sodium chloride seven times. Each washing step
consisted of turning the tube over several times, centrifuging
for 5 s with a centrifuge and discarding the supernatant.
Finally, the precipitate was suspended in 20 Al of 2% acetic
acid and the agarose was removed by filtration, using an
ultrafree-MC centrifugal 0.45 Am filter unit (Millipore, Bed-
ford, MA). The filtration was repeated twice and the pooled
filtrate was applied to LC/ESIMS.
2.3. Reversed-phase HPLC and mass spectrometry
On-line HPLC/ESIMSwas used, with a PLRP-S reversed-
phase column (1 50 mm, 1000 A˚, 8 Am; Michrom Bio-
resources, Pleasanton, CA), as reported previously [4]. An
ESI mass spectrometer, TSQ7000 (Thermo Quest, San Jose,
CA) was utilized [4]. The scanning range was m/z 500–2000
in 3 s. Calibration was performed using the peptide Met–
Arg–Phe–Ala and multiple charged ions of horse apo
myoglobin, according to the manufacturer’s instructions.
2.4. Calculation of the TTR ion peaks on ESIMS
The ratios of TTR isoforms’ ion peak heights were
determined on deconvoluted spectra, which were a summa-
tion of scans covering the whole TTR elution. The ratio of
the peak heights of S-sulfonated TTR and the sum of the
peak heights of the TTR conjugates with cysteine, cystei-
nylglycine and glutathione were calculated. Note the marks
used in Fig. 1: (S)/(B +C+D).
3. Results
Deconvoluted ESIMS spectra of TTR prepared by immu-
noprecipitation using protein G/A agarose are shown in Fig.
1. The spectrum of TTR from a control infant (Fig. 1a)
shows several peaks, which were similar to those previously
reported by the original preparation method [4,10]. The
observed mass of each peak corresponded to the theoretical
molecular weight as assigned in the figure. The assignment
of each peak was as reported previously [10]; the peak 80
Da larger than unmodified TTR was assigned to S-sulfo-
nated TTR (S). The two major peaks in the control sample
corresponded to free TTR (A) and TTR conjugated with
cysteine (B). Samples of most of the remaining controls
presented with patterns similar to that in Fig. 1a. The
spectrum from a patient with MCD (Fig. 1b) showed a
prominent S-sulfonated TTR peak, while the peaks of other
oxidized forms of TTR and free TTR were relatively low. A
similar pattern was reported for this patient using the earlier
pretreatment method [1]. Spectra obtained from the other
three MCD patients using the new method were nearly
identical to that shown in Fig. 1b.
Analysis of samples from most of the remaining controls
showed some with patterns similar to that in Fig. 1a, but
others with significantly higher signals of S-sulfonated TTR,
as shown in Fig. 1c. However, a critical difference was
noted between the spectra obtained from these controls and
those of patients with MCD. Controls with high signals of S-
sulfonated TTR also showed increased signals of TTR
conjugated with cysteine, cysteinylglycine, and (sometimes)
glutathione, while patients with MCD showed a specific
elevation of S-sulfonated TTR. Thus, the significance of the
elevated S-sulfonated TTR in any one individual is more
accurately documented by calculating the peak height ratio
of S-sulfonated TTR to that of the other oxidized derivatives
(S)/(B +C+D). The mean and S.D. of the ratio for MCD
cases (n = 4) and controls (n = 57) were 11.0F 3.8 and
0.14F 0.09, respectively (see Fig. 2).
No significant difference was found among the peak
height ratios (S-sulfonated TTR)/(all oxidized isoforms in
TTR) obtained from controls of different ages.
4. Discussion
Using an immunoprecipitation method previously
reported by us [4], serum protein was not removed com-
pletely because of the washing limit for small amounts of
precipitates (often invisible). On reversed-phase HPLC, S-
Fig. 2. Comparison of the ratio of peak height between patients with MCD
and controls, calculated by the equation: (peak height of S-sulfonated TTR)/
(the sum of the peak heights TTR conjugated with cysteine, cysteinylgly-
cine and glutathione). Note the marks used in Fig. 1: (S)/(B +C+D).
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sulfonated TTR was eluted slightly later than the other
isoforms of TTR, and co-migrated with the remaining
serum protein, mainly albumin. Using the immunoprecipi-
tation method with the help of protein G/A agarose, we
obtained clearly visible precipitates, making the washing
steps easy to perform. Sufficient washing removed the
remaining albumin, and high-quality spectra were obtained
for a wide range of TTR peaks on HPLC chromatography,
which gave an accurate peak height ratio of the signal of S-
sulfonated TTR to the sum of the signals of other TTR
isoforms. With this improved procedure, we found a clear
difference in the ratio (peak height of S-sulfonated TTR)/
(sum of peak heights of total oxidized TTR) between MCD
patients and controls.
S-sulfocysteine has been used for the diagnosis of sulfite
oxidase deficiency. However, it is a strongly acidic and
relatively unstable amino acid, which tends to be lost when
urine is desalted with the H + -form of a sulfonated ion-
exchange resin [11]. In common routine amino acid analysis
by ion-exchange chromatography, S-sulfocysteine elutes on
a position corresponding to a void volume of chromatog-
raphy, and is not separated from phosphoserine. S-sulfocys-
teine in urine can accurately be monitored by mass spectral
analysis [2], and quantitation of this metabolite is now
available as a service through the Duke University Mass
Spectrometry Laboratory [12]. The assessment of peak
height ratios proposed in this paper may represent a valuable
additional diagnostic marker. By our experiences, TTR in
plasma or sera can stay at ambient temperature for at least 1
week. S-sulfonated TTR in plasma or sera may be more
stable than S-sulfocysteine in urine.
In some control samples, the peak height of S-sulfonated
TTR was elevated in addition to that of other oxidized TTR
isoforms. The mechanism of S-sulfonated TTR formation in
control samples is unknown. We previously characterized a
unique isoform of TTR, which was 46 Da smaller than free
TTR [10]. The peak is marked by an asterisk in Fig. 1. To
characterize this isoform, the component TTR-46 prepared
by reversed phase HPLC was cleaved with trypsin. The
peptides were analyzed by LC/ESIMS, and using recon-
structed ion chromatograms, the ions corresponding to all
normal expected peptides, and the ions 46 Da smaller than
all normal peptides were plotted. A clear ion, 46 Da smaller
than mass of normal T1 + 2(M+ 2H: 729.9), was detected,
but an ion corresponding to normal T1 + 2 was not detected.
The collision-induced dissociation (CID) spectra of the
abnormal ion suggested that Cys-10 is substituted by Gly
[10]. The amino-terminal sequence of TTR-46 was also
studied with a protein sequencer, and the first 15 residues
were the same as normal sequence except position 10,
which showed Gly instead of Cys [10]. It is possible that
S-sulfonated TTR and TTR-Gly-10 are formed by an
unknown common pathway, although additional experi-
ments are needed to clarify this issue.
A European survey group has suggested that MCD is
more common than generally thought, and that patients may
well be overlooked because of a lack of awareness [13].
Although work with additional patient samples is needed to
determine the general applicability of the assay described
here, the study of TTR by ESIMS may represent a promis-
ing method for MCD screening. It may prove to be of
special value in the diagnosis of patients with isolated sulfite
oxidase deficiency, because that disorder is not associated
with disturbed purine metabolism, as in patients with MCD
deficiency, where low uric acid values can help establish the
diagnosis [2].
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